Get started
Author

Enrique Trilla

Observed names: E Trilla, E Trilla Herrera, E. Trilla, E. Trilla Herrara, E. Trilla Herrera, E. Trilla Herrera,, E. Trilla Herrero, E. Trilla herrera, E. Trilla-Herrera, Enric Trilla, Enric Trilla-Herrera, Enrique TRILLA, Enrique Tilla, Enrique Trilla Herrera, Enrique Trilla*, Trilla E, Trilla Enrique, Trilla Herrera, Enrique, Trilla Herrera,E., Trilla, Enrique
Observed institutions: Institució Catalana de Recerca i Estudis Avançats, Universitat Autònoma de Barcelona, Bellvitge University Hospital, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Puigvert Foundation, CIBBIM-Nanomedicine, Fundación Renal Española, Universitat de Barcelona
ORCID: 0000-0001-9401-0872
Observed ORCID: 0000-0001-9401-0872
OpenAlex ID: A5049082221
Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy
2007 · Juan Morote, Anna Orsola, et al. · The Journal of Urology · 255
Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer
2007 · Juan Morote, Jacques Planas Morin, et al. · Urology · 187
The reproducibility and predictive value on outcome of renal biopsies from expanded criteria donors
2013 · M. Antonieta Azancot, Francesc Moreso, et al. · Kidney International · 176
HAVCR/KIM-1 Activates the IL-6/STAT-3 Pathway in Clear Cell Renal Cell Carcinoma and Determines Tumor Progression and Patient Outcome
2014 · Thaïs Cuadros, Enric Trilla, et al. · Cancer Research · 99
Bone Mineral Density Changes in Patients With Prostate Cancer During the First 2 Years of Androgen Suppression
2006 · Juan Morote, Anna Orsola, et al. · The Journal of Urology · 97
Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer
2006 · Juan Morote, Salvador Esquena, et al. · Urologia Internationalis · 66
Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of Treatment
2003 · J Morote, E Martinez, et al. · European Urology · 63
Definition of Castrate Resistant Prostate Cancer: New Insights
2022 · Juan Morote, Adriana Aguilar, et al. · Biomedicines · 60
PDF
Effects of Holmium Laser Enucleation of the Prostate on Sexual Function
2014 · José Placer, Carlos Salvador, et al. · Journal of Endourology · 59
The relationship between daily calcium intake and bone mineral density in men with prostate cancer
2007 · Jacques Planas, Juan Morote, et al. · British Journal of Urology · 55
Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer
2004 · Juan Morote, Enrique Trilla, et al. · International Journal of Cancer · 55
PDF
The Barcelona Predictive Model of Clinically Significant Prostate Cancer
2022 · Juan Morote, Angel Borque-Fernando, et al. · Cancers · 43
PDF
Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome
2010 · Maria Carmen Mir, Enrique Trilla, et al. · British Journal of Urology · 41
Risk factors for positive findings in patients with high‐grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette‐Guérin therapy and the decision for a repeat TUR
2009 · Anna Orsola, Lluís Cecchini, et al. · British Journal of Urology · 40
Alendronate decreases the fracture risk in patients with prostate cancer on androgen‐deprivation therapy and with severe osteopenia or osteoporosis
2009 · Jacques Planas, Enrique Trilla, et al. · British Journal of Urology · 39
Hepatitis A virus cellular receptor 1/kidney injury molecule-1 is a susceptibility gene for clear cell renal cell carcinoma and hepatitis A virus cellular receptor/kidney injury molecule-1 ectodomain shedding a predictive biomarker of tumour progression
2013 · Thaïs Cuadros, Enric Trilla, et al. · European Journal of Cancer · 35
Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review
2022 · Marina Triquell, Miriam Campistol, et al. · Cancers · 30
PDF
Analysis of the Lipid Profile and Atherogenic Risk during Androgen Deprivation Therapy in Prostate Cancer Patients
2012 · C. Salvador, J. Planas, et al. · Urologia Internationalis · 28
A Randomised Controlled Trial to Assess the Benefit of Posterior Rhabdosphincter Reconstruction in Early Urinary Continence Recovery after Robot-assisted Radical Prostatectomy
2021 · Aina Salazar, Lucas Regis, et al. · European Urology Oncology · 26
Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease
2022 · Cristina Suarez, David Marmolejo, et al. · Frontiers in Oncology · 24
PDF
Litotricia extracorpórea por ondas de choque: ansiedad y percepción del dolor
2000 · C. Torrecilla Ortiz, L.L. Rodríguez Blanco, et al. · Actas Urológicas Españolas · 23
The Role of Radiomics in the Prediction of Clinically Significant Prostate Cancer in the PI-RADS v2 and v2.1 Era: A Systematic Review
2024 · Andreu Antolin, Nuria Roson, et al. · Cancers · 22
PDF
The Percentage of Free Prostatic-Specific Antigen Is Also Useful in Men with Normal Digital Rectal Examination and Serum Prostatic-Specific Antigen between 10.1 and 20 ng/ml
2002 · Juan Morote, Enrique Trilla, et al. · European Urology · 22
A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
2022 · Juan Morote, Ángel Borque-Fernando, et al. · Cancers · 21
PDF
Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer
2016 · Jacques Planas, Ana Celma, et al. · Scandinavian Journal of Urology · 21
Works count: 269
Citation count: 2,410
H-index: 22
I10-index: 58
Year
Topic
Type